To ask the Secretary of State for Health and Social Care, whether his Department will allow UK oncologists to test for genetic weaknesses by carrying out Whole Genomic Sequencing.

Genomic testing in the National Health Service in England is provided through the NHS Genomic Medicine Service and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory, which includes tests for over 7,000 rare diseases and over 200 clinical indications of cancer. Testing can be delivered using a range of technologies, including whole genome sequencing (WGS) or Next Generation Sequencing technology, large cancer gene panels, to ensure that a patient receives the most appropriate genomic testing depending on their individual circumstances.

The National Genomic Test Directory sets out the eligibility criteria for patients to access testing as well as the genomic targets to be tested and the method that should be used. For most cancers, the National Genomic Test Directory outlines that large gene panels inclusive of targets for treatments should be offered as the first line option. WGS can then be offered to any cancer patient that requires it to determine their next stage of treatment.